Raymond James Financial
PRPH

Raymond James Financial’s ProPhase Labs PRPH Stock Holding History

Raymond James Financial’s Portfolio PRPH Stock Details PRPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-20
Closed -$77 – 6296
2025
Q2 		$77 Buy
+20
New +$67 ﹤0.01% 6859

Other funds holding PRPH

SC
Sykon Capital Harrison, New York $300M AUM 16.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AWP
Accretive Wealth Partners Parsippany, New Jersey $412M AUM 15.82% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return
AWM
Apollon Wealth Management Mount Pleasant, South Carolina $8.23B AUM 30.88% 1-Year Est. Return
CD
Chapin Davis Baltimore, Maryland $569M AUM 145.59% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Raymond James Financial's PRPH Position: Q3 2025 in Review

Raymond James Financial sold out of ProPhase Labs (PRPH) in Q3 2025, closing a stake of 20 shares — an estimated $77 sold.

Raymond James Financial first reported a position in PRPH in Q2 2025 and held it in 1 quarter. The position peaked at $77 in Q2 2025. 28 funds tracked by Wall St. Rank hold PRPH as of Q3 2025.

  • Raymond James Financial reported no remaining ProPhase Labs position as of Q3 2025 after selling out during the quarter.
  • Raymond James Financial sold 20 ProPhase Labs shares in Q3 2025, an estimated $77.
  • Raymond James Financial first reported a position in ProPhase Labs in Q2 2025 and held it in 1 quarter.
  • Raymond James Financial's ProPhase Labs position peaked at $77 in Q2 2025.
  • 28 funds tracked by Wall St. Rank held ProPhase Labs as of Q3 2025.

Based on Raymond James Financial's 13F filing for Q3 2025, filed 14 Nov 2025.